Page last updated: 2024-09-03

imatinib mesylate and Cancer of Prostate

imatinib mesylate has been researched along with Cancer of Prostate in 57 studies

Research

Studies (57)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	36 (63.16)	29.6817
2010's	18 (31.58)	24.3611
2020's	3 (5.26)	2.80

Authors

Authors	Studies
Hayashi, H; Muramatsu, H; Nakamura, K; Nayeem, MJ; Sassa, N; Sato, M; Yamamura, A	1
Abur, Ü; Akgün, O; Ari, F; Aslan, S; Ergün, S; Güneş, S; Hekim, NT	1
Allahyari, A; Jafari-Nozad, AM; Maharati, A; Zangooie, A	1
Crawford, SE; Filipovich, Y; Franco, OE; Hayward, SW; Ishii, K; Katayama, N; Ohishi, K; Sasaki, T; Sugimura, Y; Takahashi, N	1
Li, WH; Li, WW; Wei, SC; Xu, L	1
Mathew, P; Rosenberg, A	1
Ferreira, J; Gutierrez, L; Parra, E	1
Teng, X; Zhou, J	1
Graziani, R; Guindani, M; Thall, PF	1
Antonarakis, ES; Lin, J; Suzman, DL; Zahurak, ML; Zhou, XC	1
Chang, I; Chiyomaru, T; Dahiya, R; Deng, G; Fukuhara, S; Gill, A; Hirata, H; Majid, S; Mitsui, Y; Nonomura, N; Saini, S; Shiina, H; Tanaka, Y; Wong, DK; Yamamura, S	1
Akan, S; Ürkmez, A; Verit, A; Yildirim, Ç; Yüksel, ÖH	1
Arioli, I; Bellone, M; Bongiovanni, L; Botti, L; Cancila, V; Chiodoni, C; Colombo, MP; Festinese, F; Jachetti, E; Parenza, M; Rigoni, A; Tardanico, R; Tripodo, C	1
Dienes, HP; Engelmann, U; Gerharz, M; Heidenreich, A; Markert, E; Ohlmann, CH; Pfister, D	1
Fidler, IJ; Horne, E; Langley, R; Mathew, P; Oborn, CJ; Papadopoulos, JN; Pettaway, CA; Pisters, LL; Thall, PF; Wen, S; Williams, DL; Wood, CG	1
Campbell-Baird, C; Costa, L; Demers, L; Harvey, H; Kim, C; Lipton, A	1
Kang, DY; Kim, S; Lee, HJ; Lim, JS; Song, IC; Yun, HJ	1
Fang, F; St Clair, DK; St Clair, WH; Sun, Y; Xu, Y	1
Ângelo, S; Moreira, JN; Pinto, AC; Simões, S	1
Moreira, JN; Pinto, AC; Simões, S	1
Dafni, H; Hu, S; Larson, PE; Ronen, SM; Venkatesh, HS; Vigneron, DB; Wang, C; Ward, CS; Yoshihara, HA; Zhang, X	1
Mathew, P; Morita, S; Thall, PF; Wen, S	1
Beumer, JH; Bitran, JD; Christner, SM; Egorin, MJ; Lestingi, TM; Nabhan, C; Tolzien, K; Valdez, TV; Villines, D	1
De la Hoz-Herazo, H; López, JI; López-Garrido, J; Macías-García, L; Pareja-Megía, MJ; Robles-Frías, A	1
Campbell, SC; Hantel, A; Kash, J; Paner, GP; Sakamoto, K; Voelzke, BB; Waters, WB	1
George, DJ	1
Fan, D; Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Logothetis, C; Mathew, P; Shepherd, DL; Tsan, R; Uehara, H	1
George, D	2
Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM	1
Fidler, IJ; Logothetis, CJ; Mathew, P	1
Fan, D; Fidler, IJ; He, J; Killion, JJ; Kim, SJ; Langley, RR; Tsan, R; Uehara, H; Yazici, S	1
Alimena, G; Breccia, M; D'Elia, GM; De Cuia, MR; Francesca, B; Mandelli, F	1
Bucana, C; Fidler, IJ; Jones, D; Kim, SJ; Logothetis, C; Mathew, P; Perez, C; Thall, PF; Troncoso, P	1
Capanna, T; Dave, N; DiPaola, RS; Doyle-Lindrud, S; Goodin, S; Juvidian, P; Levitt, MJ; Lin, Y; Rao, K; Shih, WJ	1
Battistel, C; Hartung, R; Kübler, HR; Lehmer, A; Paul, R; Treiber, U; van Randenborgh, H; Wagenpfeil, S; Wutzler, S	1
Altundag, K; Altundag, O; Gunduz, M; Morandi, P	1
Balwierz, W; Klekawka, T; Niezgoda, A; Pawińska, K; Skoczeń, S; Strojny, W	1
Blyweert, W; De Ridder, D; Debiec-Rychter, M; Ost, D; Sciot, R; Van der Aa, F; Van Oosterom, A; Van Poppel, H	1
Hofer, MD; Rubin, MA	1
Fan, D; Fidler, IJ; He, J; Kim, SJ; Langley, RR; Mathew, P; Uehara, H; Yazici, S	1
Corcoran, NM; Costello, AJ	1
Finkel, KW; Foringer, JR; Guntupalli, JS; Samuels, JA; Tjia, VM; Verani, RR	1
Febbo, PG; George, D; Golub, T; Kantoff, PW; Loda, M; Oh, WK; Rubin, MA; Thorner, A	1
Busby, JE; Do, KA; Fan, D; Fidler, IJ; He, J; Kim, SJ; Logothetis, C; Mathew, P; Maya, M; Nakamura, T; Uehara, H; Wang, X; Yazici, S	1
Fong, K; Fong, L; Lin, AM; Rini, BI; Rosenberg, JE; Ryan, CJ; Small, EJ; Weinberg, V	1
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H	1
Fidler, IJ	1
Epstein, JI; Herawi, M; Montgomery, EA	1
Balk, SP; Bubley, GJ; Masiello, D; McKnight, NC; Mohi, MG; Neel, BG; Smith, B	1
Arce-Lara, C; Benson, DM; Clinton, SK; Jimenez, RE; Monk, JP; Patel, VR; Shah, MH	1
Bubley, G; Derynck, MK; Lin, AM; Park, M; Rini, BI; Rosenberg, JE; Ryan, CJ; Small, EJ; Weinberg, V	1
Bergh, A; Johansson, A; Jones, J; Kilter, S; Pietras, K; Rudolfsson, SH; Skytt, A	1
Tan, W	1
Bucana, CD; Cohen, L; Fidler, IJ; Johnson, MM; Jones, DM; Kim, SJ; Logothetis, CJ; Mathew, P; Meluch, AA; Morris, MJ; Oh, WK; Pagliaro, LC; Smith, L; Tannir, NM; Thall, PF; Troncoso, P; Tu, SM; Wen, S	1
Abe, M; Baranowska-Kortylewicz, J; Inoue, K; Kimura, Y; Nearman, J	1
Barker, B; Dowell, JE; Ghobadi, A; Kabbani, W	1

Reviews

10 review(s) available for imatinib mesylate and Cancer of Prostate

Article	Year
Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature. Journal of medical case reports, 2023, Feb-05, Volume: 17, Issue:1 Topics: Aged, 80 and over; Humans; Imatinib Mesylate; Iran; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Multiple Myeloma; Prostatic Neoplasms; Protein Kinase Inhibitors	2023
Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:6 Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Drug Evaluation, Preclinical; Humans; Imatinib Mesylate; Male; Molecular Targeted Therapy; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Survival Rate	2013
Extraintestinal gastrointestinal stromal tumor of undetermined origin: Is the mass resection a wrong approach? A case report and review of the literature. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2015, Jul-07, Volume: 87, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Pelvic Neoplasms; Piperazines; Postoperative Care; Prostatectomy; Prostatic Neoplasms; Pyrimidines; Treatment Outcome	2015
Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances. Urology, 2002, Volume: 60, Issue:2 Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma	2002
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology, 2002, Volume: 60, Issue:3 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hormones; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Piperazines; Prostatectomy; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Treatment Outcome	2002
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. Advances in experimental medicine and biology, 2003, Volume: 532 Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Ligands; Male; Models, Biological; Mutation; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor	2003
Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Delivery Systems; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Taxoids	2004
[Perspectives in the use of imatinib in the treatment of childhood cancers]. Przeglad lekarski, 2004, Volume: 61 Suppl 2 Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Child; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Male; Neuroblastoma; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2004
[Promising new treatment options for metastatic androgen-independent prostate cancer]. Actas urologicas espanolas, 2007, Volume: 31, Issue:6 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides	2007
Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Seminars in oncology, 2001, Volume: 28, Issue:5 Suppl 17 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Isoxazoles; Leflunomide; Ligands; Male; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction	2001

Trials

11 trial(s) available for imatinib mesylate and Cancer of Prostate

Article	Year
Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome. Biometrics, 2015, Volume: 71, Issue:1 Topics: Antineoplastic Agents; Bayes Theorem; Biomarkers; Data Interpretation, Statistical; Epidemiologic Methods; Humans; Imatinib Mesylate; Male; Molecular Targeted Therapy; Outcome Assessment, Health Care; Prognosis; Prostatic Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis	2015
Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials. Prostate cancer and prostatic diseases, 2015, Volume: 18, Issue:1 Topics: Aged; Benzamides; Biomarkers; Biomarkers, Tumor; Disease-Free Survival; Humans; Hydroxamic Acids; Imatinib Mesylate; Kinetics; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Piperazines; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrimidines	2015
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases. American journal of clinical oncology, 2010, Volume: 33, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imatinib Mesylate; Imidazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Piperazines; Prognosis; Prostatic Neoplasms; Pyrimidines; Sarcoma; Survival Rate; Treatment Outcome; Zoledronic Acid	2010
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2011, Volume: 31, Issue:7 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Bone Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Imatinib Mesylate; Male; Piperazines; Placenta Growth Factor; Pregnancy Proteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Taxoids	2011
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. British journal of cancer, 2012, Aug-07, Volume: 107, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Castration; Drug Administration Schedule; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Retreatment; Sorafenib; Treatment Failure	2012
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology, 2004, Volume: 63, Issue:5 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid	2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Aug-15, Volume: 22, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Taxoids	2004
A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. The Prostate, 2005, Feb-01, Volume: 62, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Failure	2005
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU international, 2006, Volume: 98, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure	2006
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clinical genitourinary cancer, 2007, Volume: 5, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Survival Rate; Taxoids; Treatment Outcome	2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Oct-01, Volume: 13, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Castration; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Placebos; Prostatic Neoplasms; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Taxoids	2007

Other Studies

36 other study(ies) available for imatinib mesylate and Cancer of Prostate

Article	Year
Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-α. Life sciences, 2022, Jan-01, Volume: 288 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; PC-3 Cells; Prostatic Neoplasms; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2022
The Interrelationship Between Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:3 Topics: Humans; Imatinib Mesylate; Male; MicroRNAs; Promoter Regions, Genetic; Prostatic Neoplasms; Up-Regulation	2023
Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients. The Prostate, 2019, Volume: 79, Issue:3 Topics: Aged; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Kallikreins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Androgen; RNA, Messenger	2019
Malignant jejunal gastrointestinal stromal tumor with history of prostate cancer: A case report. Medicine, 2019, Volume: 98, Issue:18 Topics: Aged; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Peritoneal Neoplasms; Postoperative Complications; Prostatic Neoplasms; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome	2019
Decreased c-Abl activity in PC-3 and LNCaP prostate cancer cells overexpressing the early growth response-1 protein. Oncology reports, 2014, Volume: 31, Issue:1 Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Early Growth Response Protein 1; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; RNA Interference; RNA, Small Interfering; Tumor Necrosis Factor-alpha	2014
Primary extragastrointestinal stromal tumor of the prostate: a case report. Analytical and quantitative cytopathology and histopathology, 2014, Volume: 36, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Prostate; Prostatectomy; Prostatic Neoplasms; Pyrimidines	2014
DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells. Oncotarget, 2014, Nov-30, Volume: 5, Issue:22 Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Benzamides; Cell Line, Tumor; DNA Mismatch Repair; Heterografts; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; MutL Protein Homolog 1; Nuclear Proteins; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Transfection	2014
Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β. Molecular cancer therapeutics, 2017, Volume: 16, Issue:2 Topics: Animals; Antineoplastic Agents; Biomarkers; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mice; Mice, Transgenic; Neuroendocrine Tumors; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor beta; Seminal Vesicles; Signal Transduction; Xenograft Model Antitumor Assays	2017
[Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer]. Der Urologe. Ausg. A, 2008, Volume: 47, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Biomarkers, Tumor; Biopsy; Cetuximab; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Lymph Nodes; Male; Neoplasms, Hormone-Dependent; Piperazines; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Androgen; Taxoids; Trastuzumab	2008
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. The Journal of urology, 2009, Volume: 181, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Imatinib Mesylate; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Risk Factors; Survival Rate; Taxoids	2009
Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment. Japanese journal of clinical oncology, 2009, Volume: 39, Issue:12 Topics: Benzamides; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Sunitinib	2009
RelB-dependent differential radiosensitization effect of STI571 on prostate cancer cells. Molecular cancer therapeutics, 2010, Volume: 9, Issue:4 Topics: Androgens; Benzamides; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Survival; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; NF-kappaB-Inducing Kinase; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrimidines; Radiation Tolerance; Radiation, Ionizing; Reproducibility of Results; Transcription Factor RelA; Transcription Factor RelB	2010
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:2 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Etoposide; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Mitoxantrone; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms; Pyrimidines; Vinblastine	2011
Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer. The Prostate, 2011, Jan-01, Volume: 71, Issue:1 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Disease Models, Animal; Humans; Imatinib Mesylate; Liposomes; Male; Mice; Mice, Nude; Mitoxantrone; Piperazines; Prostatic Neoplasms; Pyrimidines; Xenograft Model Antitumor Assays	2011
Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer research, 2010, Oct-01, Volume: 70, Issue:19 Topics: Animals; Benzamides; Capillary Permeability; Carbon Isotopes; Humans; Hypoxia-Inducible Factor 1; Imatinib Mesylate; L-Lactate Dehydrogenase; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A	2010
Collision tumour involving a rectal gastrointestinal stromal tumour with invasion of the prostate and a prostatic adenocarcinoma. Diagnostic pathology, 2012, Oct-30, Volume: 7 Topics: Adenocarcinoma; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasms, Multiple Primary; Piperazines; Predictive Value of Tests; Prostate; Prostatectomy; Prostatic Neoplasms; Pyrimidines; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome	2012
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. Journal of the National Cancer Institute, 2003, Mar-19, Volume: 95, Issue:6 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microcirculation; Neoplasms, Experimental; Paclitaxel; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Radiographic Image Enhancement; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Tumor Cells, Cultured	2003
Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer research, 2004, Jun-15, Volume: 64, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Substrate Specificity; Xenograft Model Antitumor Assays	2004
Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia. Haematologica, 2004, Volume: 89, Issue:7 Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Multiple Primary; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Testis; Testosterone	2004
In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. The Prostate, 2005, Jun-01, Volume: 63, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Drug Synergism; Estramustine; Etoposide; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Male; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Taxoids	2005
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology, 2005, Volume: 65, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Diphosphonates; Humans; Imatinib Mesylate; Imidazoles; Male; Neoplasm Proteins; Palliative Care; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Failure; Zoledronic Acid	2005
Gastrointestinal stromal tumor of the prostate. Urology, 2005, Volume: 65, Issue:2 Topics: Acute Disease; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography; Sarcoma; Urinary Retention; Weight Loss	2005
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-20, Volume: 23, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Docetaxel; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Research Design; Taxoids	2005
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer research, 2005, May-01, Volume: 65, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Nude; Osteoclasts; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Zoledronic Acid	2005
Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer. BJU international, 2005, Volume: 96, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Drug Administration Schedule; Drug Synergism; Fluorescent Antibody Technique; Imatinib Mesylate; Male; Mice; Mice, SCID; Models, Animal; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Treatment Failure	2005
Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:12 Topics: Acute Kidney Injury; Benzamides; Humans; Imatinib Mesylate; Kidney; Kidney Function Tests; Male; Middle Aged; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis	2005
Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-01, Volume: 12, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Benzamides; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Immunohistochemistry; Lasers; Male; Microdissection; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrimidines	2006
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. Journal of the National Cancer Institute, 2006, Jun-07, Volume: 98, Issue:11 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tibia; Tumor Cells, Cultured	2006
[Molecular-targeted therapy for hormone-refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6 Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D	2006
Antivascular therapy of cancer metastasis. Journal of surgical oncology, 2006, Sep-01, Volume: 94, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor	2006
Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: A clinicopathologic study of 8 cases. The American journal of surgical pathology, 2006, Volume: 30, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biopsy, Needle; Combined Modality Therapy; Diagnosis, Differential; Digestive System Surgical Procedures; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Prostate; Prostatic Neoplasms; Pyrimidines	2006
Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer biology & therapy, 2007, Volume: 6, Issue:2 Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome	2007
Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach. Urology, 2007, Volume: 69, Issue:6 Topics: Antineoplastic Agents; Benzamides; Biopsy, Needle; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Unknown Primary; Piperazines; Prostatic Neoplasms; Pyrimidines; Treatment Outcome	2007
A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. The Prostate, 2007, Nov-01, Volume: 67, Issue:15 Topics: Adenocarcinoma; Androgen Receptor Antagonists; Angiopoietins; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Imatinib Mesylate; Immunoglobulin Fc Fragments; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Orchiectomy; Piperazines; Prostate; Prostatic Neoplasms; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor beta; Receptor, TIE-2; Receptors, Androgen; Recombinant Fusion Proteins; Stromal Cells; Xenograft Model Antitumor Assays	2007
PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer. Cancer biology & therapy, 2007, Volume: 6, Issue:11 Topics: Animals; Antineoplastic Agents; Becaplermin; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Insulin-Like Growth Factor I; Male; Mice; Mice, Nude; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Proto-Oncogene Proteins c-sis; Pyrimidines; Radioimmunotherapy; Receptor, Platelet-Derived Growth Factor beta	2007
Rectal GI stromal tumor mimicking a prostate mass. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Dec-20, Volume: 25, Issue:36 Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Pelvic Exenteration; Piperazines; Prostatic Neoplasms; Pyrimidines; Rectal Neoplasms	2007